In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Non-cardiac comorbidities in HFrEF, HFmrEF and HFpEF - findings from BIOSTAT-CHF

Session Poster Session 2

Speaker Koen Streng

Event : Heart Failure 2017

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Comorbidities
  • Session type : Poster Session

Authors : K W Streng (Groningen,NL), JF Nauta (Groningen,NL), JL Hillege (Groningen,NL), SD Anker (Gottingen,DE), JG Cleland (London,GB), CC Lang (Dundee,GB), M Metra (Brescia,IT), L Ng (Leicester,GB), P Ponikowski (Wroclaw,PL), DJ Van Veldhuisen (Groningen,NL), A Zwinderman (Amsterdam,NL), F Zannad (Nancy,FR), K Damman (Groningen,NL), P Van Der Meer (Groningen,NL), AA Voors (Groningen,NL)

K W Streng1 , JF Nauta1 , JL Hillege1 , SD Anker2 , JG Cleland3 , CC Lang4 , M Metra5 , L Ng6 , P Ponikowski7 , DJ Van Veldhuisen1 , A Zwinderman8 , F Zannad9 , K Damman1 , P Van Der Meer1 , AA Voors1 , 1University Medical Center Groningen, Department of Cardiology - Groningen - Netherlands , 2University Medical Center Gottingen (UMG), Innovative Clinical Trials, Department of Cardiology and Pneumology - Gottingen - Germany , 3Imperial College London, National Heart & Lung Institute, Royal Brompton and Harefield Hospitals - London - United Kingdom , 4University of Dundee, School of Medicine Centre for Cardiovascular and Lung Biology - Dundee - United Kingdom , 5University of Brescia, Institute of Cardiology, Department of Medical and Surgical Specialties - Brescia - Italy , 6University of Leicester, Department of Cardiovascular Sciences - Leicester - United Kingdom , 7Wroclaw Medical University, Department of Heart Diseases - Wroclaw - Poland , 8Academic Medical Center of Amsterdam, Department of Epidemiology, Biostatistics and Bioinformatics - Amsterdam - Netherlands , 9University of Lorraine - Nancy - France ,

European Journal of Heart Failure ( 2017 ) 19 ( Suppl. S1 ), 268

Background: Comorbidities play a major role in heart failure. Whether prevalence and prognostic importance of comorbidities differ between heart failure with preserved ejection fraction (HFpEF), mid-range (HFmrEF) or reduced ejection fraction (HFrEF) is unknown.
Methods: Patients from the index (n=2516) and validation cohort (n=1738) of The BIOlogy Study to Tailored Treatment in Chronic Heart Failure (BIOSTAT-CHF) were pooled for the present analysis. Seven non-cardiac comorbidities were assessed; diabetes mellitus, thyroid dysfunction, obesity, anaemia, chronic kidney disease (CKD), COPD and stroke. Patients were classified into 6 groups based on ejection fraction; HFrEF(<40%), HFmrEF (40-50%) and HFpEF (=50%), and having less or more than 3 comorbidities. Impact of each comorbidity on all-cause mortality was evaluated by population attributable risk (PAR).
Results: Patients with known LVEF and complete comorbidity data were included (n=3499). Most prevalent comorbidity was CKD, with a prevalence of 50%. All comorbidities had a higher prevalence in HFpEF, except for stroke. Patients with 3 or more comorbidities had higher all-cause mortality rates in HFrEF (hazard ratio (HR) 1.57, P<0.001) and HFmrEF (HR 1.39, P<0.001), but not in HFpEF (HR 1.02, P=0.902). Highest PARs were seen for CKD in all HF groups, whereas obesity has an inverse PAR in HFpEF. Diabetes and stroke contributed significantly in HFrEF (11% and 6%) but were not significant in HFpEF (-1% and 0%).
Conclusions: Overall, comorbidities are more prevalent in patients with HFpEF, but having more comorbidities is associated with an increased all-cause mortality in HFrEF and HFmrEF, but not in HFpEF. CKD has the highest impact on mortality in all groups. History of stroke and diabetes have a significant impact on all-cause mortality in HFrEF, in contrast to HFmrEF and HFpEF.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are